 BEIJING, Oct. 17, 2019 PRNewswire -- China Biologic Products Holdings, Inc. NASDAQ: CBPO, China Biologic or the Company, a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the special committee the Special Committee of the Companys board of directors the Board has retained Duff Phelps, LLC and Duff Phelps Securities, LLC as its financial advisor and Davis Polk Wardwell LLP as its legal counsel in connection with its review and evaluation of the previously announced preliminary non-binding going private proposal from Beachhead Holdings Limited, CITIC Capital China Partners IV, L.P., PW Medtech Group Limited, Parfield International Ltd., HH Sum-XXII Holdings Limited and V-Sciences Investments Pte. Ltd the Proposal. 